Ness Ziona, Israel, January 30, 2018 — Mapi Pharma Ltd announced today that the first patient has been treated with GA Depot in the company’s Phase II study for primary progressive multiple sclerosis (PPMS). Glatiramer acetate, the active material of...
Data Suggest that GA Depot Has Potential to Ease the Treatment Burden and Improve Patient Compliance in MS Patients on GA Depot Achieved a No Evidence of Disease Activity (NEDA) Score of 84.6% Phase III Trial Planned for 2018 NESS ZIONA, Israel – Oct. 31, 2017 – Mapi...
NESS ZIONA, Israel, August 17, 2017. Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli...
Ness Ziona, Israel, May 27, 2015 — Mapi Pharma Ltd. announced today that Shavit Capital has led an investment round of $10 million in the company in a Series A financing round that included participation by the company’s chairman and CEO Mr. Ehud Marom. The...
The monthly injection of GA Depot is intended to replace current treatments for RRMS including the daily or thrice-weekly injection of Copaxone® Ness Ziona, Israel, December 17, 2014 — Mapi Pharma Ltd. announced today that the first patient was treated in...
Ness Ziona, Israel, May 27, 2014 —- Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company’s Glatiramer Acetate Depot has been extended until... 